BNP Paribas Financial Markets
OMED

BNP Paribas Financial Markets’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

BNP Paribas Financial Markets’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-315
Closed -$2.9K – 4435
2017
Q1 		$2.9K Sell
315
-184
-37% -$1.62K ﹤0.01% 3437
2016
Q4 		$3.85K Sell
499
-1,028
-67% -$9.45K ﹤0.01% 3792
2016
Q3 		$17.5K Buy
1,527
+881
+136% +$10.3K ﹤0.01% 2969
2016
Q2 		$7.95K Buy
+646
New +$7.84K ﹤0.01% 3033
2016
Q1 		– Sell
-3,338
Closed -$75.2K – 3581
2015
Q4 		$75.2K Sell
3,338
-171
-5% -$3.5K ﹤0.01% 2520
2015
Q3 		$58.2K Buy
3,509
+2,102
+149% +$42.1K ﹤0.01% 2752
2015
Q2 		$31.7K Buy
1,407
+1,106
+367% +$27.3K ﹤0.01% 2757
2015
Q1 		$7.76K Buy
+301
New +$7.63K ﹤0.01% 2893
2014
Q4 		– Sell
-1,261
Closed -$23.9K – 4165
2014
Q3 		$23.9K Buy
+1,261
New +$25.3K ﹤0.01% 3050

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BNP Paribas Financial Markets's OMED Position: Q2 2017 in Review

BNP Paribas Financial Markets sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2017, closing a stake of 315 shares — an estimated $2.9K sold.

BNP Paribas Financial Markets first reported a position in OMED in Q3 2014 and held it in 9 quarters. The position peaked at $75.2K in Q4 2015. 68 funds tracked by Wall St. Rank hold OMED as of Q2 2017.

  • BNP Paribas Financial Markets reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 315 OncoMed Pharmaceuticals, Inc. shares in Q2 2017, an estimated $2.9K.
  • BNP Paribas Financial Markets first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2014 and held it in 9 quarters.
  • BNP Paribas Financial Markets's OncoMed Pharmaceuticals, Inc. position peaked at $75.2K in Q4 2015.
  • 68 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2017.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2017, filed 3 Aug 2017.